Profile data is unavailable for this security.
About the company
Emergent BioSolutions, Inc. is a life sciences company. It is focused on providing preparedness and response solutions addressing accidental, deliberate and naturally occurring public health threats. Its solutions include a product portfolio, a product development portfolio, and a Bioservices portfolio. Its segments include Commercial Products, MCM Products, and Services Segment. Commercial Products segment include NARCAN (naloxone HCl). MCM Products segment consists of its Anthrax - MCM, Smallpox - MCM and Other Products. Services segment consisting of its Bioservices offerings. NARCAN (naloxone HCl) Nasal Spray, an intranasal formulation of naloxone is developed for the emergency treatment of known or suspected opioid overdose as manifested by respiratory and/or central nervous system depression. Its portfolio of Bioservices consists of three but interrelated service pillars, such as development services (process and analytical development) and drug substance manufacturing.
- Revenue in USD (TTM)1.19bn
- Net income in USD-565.30m
- Incorporated2003
- Employees1.60k
- LocationEmergent BioSolutions Inc400 Professional Dr, Suite 400GAITHERSBURG 20879United StatesUSA
- Phone+1 (240) 631-3200
- Fax+1 (240) 631-3203
- Websitehttps://emergentbiosolutions.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Monte Rosa Therapeutics Inc | 1.06m | -135.28m | 256.13m | 133.00 | -- | 1.39 | -- | 240.72 | -2.53 | -2.53 | 0.0197 | 3.04 | 0.0037 | -- | 0.768 | 8,000.00 | -46.99 | -- | -52.64 | -- | -- | -- | -12,714.47 | -- | -- | -- | 0.00 | -- | -- | -- | -24.75 | -- | -- | -- |
| Invivyd Inc | 0.00 | -206.82m | 257.72m | 94.00 | -- | 1.44 | -- | -- | -1.86 | -1.86 | 0.00 | 1.50 | 0.00 | -- | -- | 0.00 | -73.08 | -- | -81.48 | -- | -- | -- | -- | -- | 5.77 | -- | 0.00 | -- | -- | -- | 17.68 | -- | -- | -- |
| Actinium Pharmaceuticals Inc | 81.00k | -46.45m | 257.92m | 49.00 | -- | 5.80 | -- | 3,184.26 | -1.72 | -1.72 | 0.003 | 1.49 | 0.0009 | -- | -- | 1,653.06 | -48.80 | -46.98 | -53.25 | -52.71 | -- | -- | -57,346.91 | -6,683.95 | -- | -- | 0.0006 | -- | -92.14 | -- | -47.86 | -- | 9.75 | -- |
| Sanara Medtech Inc | 68.00m | -4.89m | 261.17m | 107.00 | -- | 6.03 | -- | 3.84 | -0.5873 | -0.5873 | 8.15 | 5.02 | 1.04 | 1.99 | 8.63 | 635,556.60 | -7.68 | -17.73 | -9.30 | -22.07 | 88.80 | 88.08 | -7.39 | -17.13 | 1.02 | -9.21 | 0.184 | -- | 41.77 | 61.93 | 45.79 | -- | 99.09 | -- |
| XBiotech Inc | 0.00 | -30.74m | 261.63m | 92.00 | -- | 1.25 | -- | -- | -1.01 | -1.01 | 0.00 | 6.87 | 0.00 | -- | -- | 0.00 | -13.08 | 31.88 | -13.68 | 33.27 | -- | -- | -- | 877.30 | -- | -- | 0.0456 | 0.00 | -100.00 | -- | 25.36 | -- | 24.30 | -- |
| TriSalus Life Sciences Inc | 21.98m | -68.07m | 262.90m | 112.00 | -- | -- | -- | 11.96 | -2.09 | -2.09 | 0.7291 | -1.31 | 1.17 | 1.26 | 7.49 | 196,276.80 | -339.18 | -- | -11,196.50 | -- | 86.74 | -- | -291.08 | -- | 0.714 | -16.82 | -- | -- | 49.31 | -- | -26.51 | -- | -- | -- |
| Emergent Biosolutions Inc | 1.19bn | -565.30m | 263.06m | 1.60k | -- | 0.3962 | -- | 0.2219 | -10.87 | -10.87 | 22.86 | 12.67 | 0.4988 | 1.99 | 6.09 | 740,875.00 | -23.79 | -2.94 | -38.89 | -3.66 | 41.19 | 53.24 | -47.69 | -5.95 | 0.5538 | 0.0636 | 0.5771 | -- | -6.10 | 6.05 | -259.40 | -- | -4.29 | -- |
| ASP Isotopes Inc | 1.27m | -19.62m | 263.47m | 76.00 | -- | 23.52 | -- | 206.91 | -0.5335 | -0.5335 | 0.0344 | 0.2164 | 0.0425 | -- | -- | 16,755.00 | -65.49 | -- | -81.59 | -- | 32.81 | -- | -1,542.66 | -- | -- | -17.39 | 0.633 | -- | -- | -- | -229.34 | -- | -- | -- |
| Rani Therapeutics Holdings Inc | 0.00 | -33.08m | 264.20m | 140.00 | -- | 34.16 | -- | -- | -1.29 | -1.29 | 0.00 | 0.1534 | 0.00 | -- | -- | 0.00 | -87.80 | -- | -140.92 | -- | -- | -- | -- | -- | -- | -28.75 | 0.6695 | -- | -- | -- | -11.06 | -- | -- | -- |
| Acrivon Therapeutics Inc | 0.00 | -64.12m | 264.62m | 58.00 | -- | 1.80 | -- | -- | -2.88 | -2.88 | 0.00 | 4.77 | 0.00 | -- | -- | 0.00 | -44.11 | -- | -46.46 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -93.76 | -- | -- | -- |
| Medifast Inc | 897.81m | 67.76m | 268.29m | 634.00 | 3.96 | 1.27 | 3.31 | 0.2988 | 6.20 | 6.20 | 82.15 | 19.29 | 2.88 | 3.37 | -- | 1,416,106.00 | 21.71 | 41.25 | 32.62 | 69.38 | 73.15 | 73.20 | 7.55 | 10.06 | 2.25 | -- | 0.00 | 49.18 | -32.94 | 16.43 | -30.75 | 12.25 | 5.59 | 17.72 |
| Adaptimmune Therapeutics PLC - ADR | 18.36m | -163.41m | 268.34m | 449.00 | -- | 11.01 | -- | 14.62 | -0.7285 | -0.7285 | 0.0834 | 0.0954 | 0.0672 | -- | 3.63 | 40,886.41 | -59.85 | -41.19 | -78.55 | -48.21 | -- | -- | -890.13 | -714.26 | -- | -- | 0.00 | -- | 122.05 | 0.2595 | 31.18 | -- | 0.7202 | -- |
| Metagenomi Inc | 44.76m | -68.26m | 268.62m | 236.00 | -- | -- | -- | 6.00 | -1.82 | -1.82 | 1.19 | 5.73 | -- | -- | -- | 189,644.10 | -- | -- | -- | -- | -- | -- | -152.50 | -- | -- | -- | 0.00 | -- | 160.21 | -- | -56.57 | -- | -- | -- |
| Enanta Pharmaceuticals Inc | 72.88m | -131.74m | 271.31m | 145.00 | -- | 1.63 | -- | 3.72 | -6.25 | -6.25 | 3.46 | 7.84 | 0.197 | -- | 5.70 | 502,627.60 | -35.60 | -14.56 | -40.33 | -15.62 | -- | -- | -180.75 | -54.96 | -- | -- | 0.0085 | -- | -8.07 | -17.45 | -9.91 | -- | 24.89 | -- |
| Century Therapeutics Inc | 1.37m | -133.47m | 273.40m | 152.00 | -- | 1.20 | -- | 199.56 | -2.22 | -2.22 | 0.0227 | 2.74 | 0.0034 | -- | -- | 9,013.16 | -33.17 | -- | -35.08 | -- | -- | -- | -9,742.41 | -- | -- | -- | 0.00 | -- | -57.01 | -- | -4.38 | -- | -- | -- |
| ESSA Pharma Inc | 0.00 | -27.73m | 275.05m | 50.00 | -- | 2.06 | -- | -- | -0.6282 | -0.6282 | 0.00 | 3.01 | 0.00 | -- | -- | 0.00 | -18.71 | -23.01 | -19.12 | -23.67 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 24.27 | -- | -- | -- |
Data as of May 24 2024. Currency figures normalised to Emergent BioSolutions Inc's reporting currency: US Dollar USD
40.27%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 31 Mar 2024 | 5.06m | 9.70% |
| Charles Schwab Investment Management, Inc.as of 31 Mar 2024 | 4.15m | 7.95% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 3.37m | 6.46% |
| Avidity Partners Management LPas of 31 Mar 2024 | 1.91m | 3.66% |
| BlackRock Advisors LLCas of 31 Mar 2024 | 1.18m | 2.25% |
| Geode Capital Management LLCas of 31 Mar 2024 | 1.12m | 2.15% |
| Two Sigma Advisers LPas of 31 Mar 2024 | 1.07m | 2.06% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 1.06m | 2.03% |
| AQR Capital Management LLCas of 31 Mar 2024 | 1.05m | 2.02% |
| Morgan Stanley & Co. LLCas of 31 Mar 2024 | 1.05m | 2.01% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
